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Abstract: Our previous studies revealed that graphene had anticancer properties in 
experiments in vitro with glioblastoma multiforme (GBM) cells and in tumors cultured  
in vivo. We hypothesized that the addition of arginine or proline to graphene solutions might 
counteract graphene agglomeration and increase the activity of graphene. Experiments were 
performed in vitro with GBM U87 cells and in vivo with GBM tumors cultured on chicken 
embryo chorioallantoic membranes. The measurements included cell morphology, mortality, 
viability, tumor morphology, histology, and gene expression. The cells and tumors were 
treated with reduced graphene oxide (rGO) and rGO functionalized with arginine (rGO + Arg) 
or proline (rGO + Pro). The results confirmed the anticancer effect of graphene on GBM 
cells and tumor tissue. After functionalization with amino acids, nanoparticles were 
distributed more specifically, and the flakes of graphene were less agglomerated. The molecule 
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of rGO + Arg did not increase the expression of TP53 in comparison to rGO, but did not 
increase the expression of MDM2 or the MDM2/TP53 ratio in the tumor, suggesting that 
arginine may block MDM2 expression. The expression of NQO1, known to be a strong 
protector of p53 protein in tumor tissue, was greatly increased. The results indicate that the 
complex of rGO + Arg has potential in GBM therapy. 
Keywords: graphene; reduced graphene oxide; amino acids; glioblastoma multiforme; cells; 
tumor; gene expression 
 
1. Introduction 
Primary brain tumors represent about 2% of all malignant tumors in adults; 50%–60% of these are 
astrocyte gliomas [1]. Although these tumors are relatively uncommon, they unfortunately generate  
major clinical problems because of their infiltrative growth, aggressive character and progression to 
malignancy [2]. Glioblastoma multiforme (GBM) is extremely aggressive and the most lethal type  
of brain tumor. After diagnosis the median patient survival is approximately one year [3,4]. Major 
challenges in the therapy of GBM are associated with the tumor location within the brain, which greatly 
complicates surgical removal, and the fact that pharmacological therapy is extremely harmful to 
healthy tissues [5]. Consequently, research into new methods for GBM therapy that minimize side 
effects remains indispensable. 
Graphene, a single atomic layer of sp2-bonded carbons [6], and graphene oxide have been recently 
investigated as nanostructures useful in anticancer treatment. There are two main avenues to this 
research. The first is focused on the use of graphene as a delivery platform [7–9]. The second trend is 
focused on graphene as a drug-like structure possessing anticancer activity [10,11]. However, the 
behavior of graphene within an organism is still controversial, regardless of its application. 
The most important factor is that the solubility of graphene in water is low [12], which consequently 
affects the transportation and utilization of graphene within an organism; thus, graphene shows a 
tendency to agglomerate and form deposits at the site of administration [13]. This characteristic may 
positively limit the range of graphene penetration into healthy tissue when administered into tumor 
tissue, but negatively decreases its activity due to a reduced surface area after agglomeration. 
Our previous studies revealed that graphene had anticancer properties in in vitro experiments with 
GBM cells and in experiments with GBM tumors cultured in vivo [14]. We demonstrated that graphene 
enters into GMB cells and other cells in GMB tissue, causing severe destruction of cells by triggering 
apoptosis. However, nanoparticles of graphene deposited within tissue or cells showed a tendency to 
agglomerate, which probably decreased the graphene-biostructure interface within the tissue and/or  
cell. We hypothesized that the addition of amino acids to graphene solutions might counteract graphene 
agglomeration. Moreover, amino acids, which are natural, small molecules involved in specific 
interactions with other molecules, inside and outside cells, may increase anchoring of graphene in the 
area of amino acids specific localizations, and prevent agglomeration of graphene. The role of proteins 
as a cargo for carbon nanotubes, when proteins are enabled as internal loads or for external adsorption 
of nanotubes, was also suggested [15]. 
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Amino acids show natural affinity for graphene surface, interestingly they bind graphene surface 
according to the structure of side-chain groups [16]. Proline has a unique structure among the common 
amino acids, having its side chain cyclized onto the backbone nitrogen atom, which is the main reason 
why proline is a common binding motif [17]. The unique structure of proline distinguishes it from other 
amino acids, in terms of chemical stability and inelasticity [18]. Proline is a hydrophobic amino acid 
capable of binding to aromatic residues [19], which may mediate its affinity for graphene, however, the 
affinity of proline for graphene is small, compared to other amino acids [16]. The binding of proline to 
graphene may influence the spread of graphene particles in the tissue and increase resistance to 
agglomeration; consequently, graphene + proline molecules may occupy a larger area in the tumor  
tissue. Proline participates in the induction and progression of cellular stress [20,21] and in molecular 
recognition, particularly in intracellular signaling [19], and also participates in signaling mechanisms, 
particularly those occurring via protein-protein recognition without a translational pathway [22].  
The regulatory effect of proline metabolism is connected to stress dependent on p53 regulation, because 
the first enzyme in the proline degradation pathway (proline oxidase/proline dehydrogenase) is encoded 
by p53-induced gene 6 (PIG6) and induces metabolic responses under stress conditions. One of the most 
promising anticancer strategies involves exploring the possibilities of p53 protein activation by blocking 
its binding to MDM2 [23]. Other key studies [24] concerning polymorphisms of p53 demonstrated that 
this protein also occurs in a form containing arginine instead of proline in the N-terminal domain, which 
increases its proapoptotic activity by 15-fold. The results of other studies have suggested that the 
methylation of arginine may play a role in regulating different biochemical properties of p53 that have 
downstream consequences on the functional result of the p53 response [25]. Moreover, according to 
Jeong et al. [26] the greatest difference between p53-arginine and p53-proline was demonstrated for the 
PERP gene engaged in cell-cell adhesion and apoptosis. The most common genes that are transcribed 
more efficiently by the p53-arginine protein than the p53-proline protein are related to apoptotic function 
(DR4, NOXA, PUMA, and PIG3). Other studies have also confirmed the participation of arginine in 
protecting the redox state in cells [27]. Furthermore, arginine as a source of nitric oxide can modify the 
formation of reactive forms of oxygen in mitochondria and lead to apoptosis. Interestingly, arginine 
showed the highest affinity for graphene, in comparison to all amino acids [16]. 
Therefore, proline or arginine may not only protect graphene against agglomeration but also support 
its anticancer properties. Proline and arginine are perceived as anti-cancer molecules [21,28–30]. In the 
present study, however, it was investigated as to whether amino acids might play a role as a cargo for 
graphene, supporting its navigation and deposition in tumor tissue, and hence modulate the toxicity of 
graphene, and also act as potential anti-cancer agents. We hypothesized that counteracting graphene 
agglomeration within tissue/cells may increase the range of graphene activity. Therefore, we investigated 
the other trend in anticancer graphene use, where graphene as an anticancer drug is delivered and 
distributed by organic compounds (amino acids), which also support the anticancer activity of graphene 
and create a kind of mutual cooperation. 
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2. Results 
2.1. Characterization of GO (Graphene Oxide) and rGO (Reduced Graphene Oxide) 
Figure 1 shows representative TEM (transmission electron microscope) images of GO (A), rGO (B), 
rGO + Arg (C), rGO + Pro (D). GO after reduction, a change in morphology was seen, with fewer layers, 
and irregular and wrinkled flakes, ranging from 100 nm to 1.5 μm in diameter. After functionalization 
of GO with arginine and proline, graphene and amino acids changed their appearance. Graphene was 
attached to the amino acids, and there were no visible free flakes of graphene, the structures were 
irregular and branch like. 
 
Figure 1. TEM image of graphene oxide (A); reduced graphene oxide (B); and reduced 
graphene oxide functionalised with arginine (C) and proline (D). The ζ potentials were for 
rGO: 19.5, rGO + Arg: 32.5, rGO + Pro: 39.8, Arg: 9.67 and Pro: 23.8 mV. 
The Fourier transform infrared spectroscopy (FTIR) spectrum of rGO, rGO + Arg and rGO + Pro 
samples indicate the presence of amino acids grafted by rGO (Figure 2). Both spectra of graphene 
functionalized with amino acids are similar and differ from rGO spectra. In the rGO characteristic 
spectrum, three peaks at 1769, 1602 and 1289 cm−1 were observed, corresponding to C=O, C=C and  
C–O bonds respectively [31]. The spectrum of rGO + Arg and rGO + Pro samples showed presence of 
groups originated from amino acids functionalization, observed also by the other authors in the spectra 
of arginine [32], graphene functionalized with poly-L-lysine [33] and graphene functionalized with 
amine [34]. In the range from 3500 to 3140 cm−1, stretching bands derived from O–H group and N–H in 
free NH3+ group was observed. At around 1570 cm−1 there is out-of-plane bending of NH2 group and at 
around 1236 cm−1 overlap C–O and also C–N stretching is seen. Bending vibrations of N–H groups are 
in the range of 890–810 cm−1. At 454 cm−1 in the sample with arginine and at 463 cm−1 in the sample 
with proline there are bands due to rocking motion of N–H groups. The C=O stretching vibration, 
corresponding to carboxylic groups, appears at 1725 cm−1. 
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Figure 2. Fourier transform infrared spectroscopy spectra of reduced graphene oxide  
(top left) and reduced graphene oxide with arginine and with proline. 
2.2. Experiments with Fibroblast and Glioblastoma Cells 
Mortality, Viability and Morphology of Cells 
In the preliminary experiments with fibroblast L929 the morphology of cells after treatment with rGO 
differed from the control group. Fewer cells were seen and with graphene agglomerates attached to the 
cell body (Figure 3B). rGO significantly (p < 0.05) decreased viability of both cell lines comparing with 
the control groups. However, the reduction of GBM cells was significantly higher than fibroblast cells 
(Figure 3C). 
 
Figure 3. Morphology of L929 fibroblast cells in the control group (A); after treatment with 
reduced graphene oxide (B) and the viability of cells (C). Notes: Reduced graphene oxide 
flakes formed agglomerates and adhered to the cells. Bars with different superscripts indicate 
significant differences between groups (p < 0.05); error bars are standard deviations. C 
Fibrobl: control fibroblasts (untreated); rGO Fibrobl: fibroblasts treated with reduced 
graphene oxide; C GMB: control glioblastoma (untreated); and rGO GMB: glioblastoma 
treated with reduced graphene oxide. 
The measurements of mortality demonstrated that rGO flakes significantly (p <0.05) increased the 
number of dead cells compared with the control group. The complexes of rGO + Arg and rGO + Pro 
also significantly increased cell mortality but to lesser extent than rGO (Figure 4). 
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Figure 4. Effect of reduced graphene oxide, reduced graphene oxide with arginine, and 
reduced graphene oxide with proline on the mortality of glioblastoma U87 cells. Notes: Bars 
with different superscripts indicate significant differences between groups (p < 0.05); error 
bars are standard deviations. C: control group (untreated cells); rGO: reduced graphene oxide 
group; rGO + Arg: reduced graphene oxide with arginine group; and rGO + Pro: reduced 
graphene oxide with proline group. 
After treatment with rGO, the viability of U-87 cells was reduced, but functionalization of graphene 
with Arg and Pro overcame this negative effect of graphene, and U-87 cell viability was not affected by 
rGO + Arg and rGO + Pro (Figure 5). 
 
Figure 5. Effect of reduced graphene oxide, reduced graphene oxide with arginine, and 
reduced graphene oxide with proline on the viability of U87 glioblastoma cells. Notes: Bars 
with different superscripts indicate significant differences between groups (p < 0.05); error 
bars are standard deviations. C: control group (untreated cells); rGO: reduced graphene 
oxide; rGO + Arg: reduced graphene oxide with arginine; rGO + Pro: reduced graphene 
oxide with proline. 
The morphology of GBM cells after treatment with rGO differed from the control. Fewer cells were 
seen with reduced protrusion and with graphene agglomerates attached to the cell body (Figure 6).  
rGO + Arg and rGO + Pro did not visibly change the morphology of cells; however, black spots of rGO 
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agglomerates were not seen, and only small shadows were observed on the body of cells. In the group 
of cells treated with rGO + Arg, graphene was nearly invisible. 
 
Figure 6. Morphology of U-87 glioblastoma cells in the control group (A) and after 
treatment with reduced graphene oxide (B), reduced graphene oxide with arginine (C),  
and reduced graphene oxide with proline (D). Notes: Reduced graphene oxide flakes formed 
agglomerates (B), all graphene forms adhered to the cells. 
2.3. Experiments with Tumor Tissue 
2.3.1. The Volume, Weight and Morphology of GBM Tumors 
GBM U-87 cells were cultured on the chorioallantoic membranes of chicken embryos. The tumor 
tissue was resected, and the volume, weight and morphology of the tumors were compared (Table 1). 
Table 1. Characteristics of glioblastoma multiforme U87 tumors cultured on chicken embryo 
chorioallantoic membrane after treatment with reduced graphene oxide, reduced graphene 
oxide with arginine and reduced graphene oxide with proline or untreated as a control. 
Parameter 
Group ANOVA 
Control rGO rGO + Arg rGO + Pro SE p-Value 
Weight [mg] 0.0981 a 0.0637 b 0.0666 b 0.0598 b 0.01551 0.0317 
Volume [mm3] 114.2 a 45.32 b 74.51 b 64.12 b 18.481 0.0049 
a,b Values with different superscripts denote a statistically significant difference (p < 0.05) between the 
treatments. Abbreviations: control group (untreated); rGO: reduced graphene oxide group; rGO + Arg: reduced 
graphene oxide with arginine group; rGO + Pro: reduced graphene oxide with proline group; ANOVA: analysis 
of variance; and SE: pooled standard error. 
rGO and rGO functionalized with arginine and proline significantly reduced the weight of the tumors. 
The volume of the tumors after treatment with rGO, rGO + Arg, and rGO + Pro was reduced in 
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comparison to the control; however, the greatest reduction was observed with rGO. The morphology of 
the tumors after treatment with rGO differed from the control (Figure 7). 
 
Figure 7. Morphology of U-87 glioblastoma tumors cultured on chicken embryo 
chorioallantoic membranes in the control group (A) and after treatment with reduced 
graphene oxide (B); reduced graphene oxide with arginine (C); and reduced graphene oxide 
with proline (D). 
The solid part of the tumor was less rounded, wrinkled and creased with fewer visible blood vessels. 
Dark grey or black spots of graphene agglomerates were seen. After treatment with rGO + Arg, solid 
parts of tumors were smaller and rounded without wrinkles; however, comparing to the other groups, 
the network of blood vessels reduced to the greatest extent. rGO + Pro also decreased the solid volume 
of the tumor, but did not change the surface morphology. Graphene particles were easily visible. 
2.3.2. Histology of Tumors 
Pictures of the control GBM tumor presented a typical microstructure (Figure 8). Two basic 
morphologic features were seen: necrosis and endothelial proliferation. Centrally located necrosis and 
palisading cells around necrotic foci were observed. Formations of blood vessels were also noted, mainly 
in the outer layer of the tumor. The presence of pink fibrillary cytoplasm in the cells was also seen. 
Images of the GBM tumors treated with rGO indicated the presence of graphene agglomerates within 
the tissue. rGO was randomly distributed in the central area of the tumor as well as in the core. The 
tissue, however, was full of white gaps and ruptures. GBM tumors, after injection with rGO + Arg and 
rGO + Pro, appeared different. In the rGO + Arg group, graphene was placed on the outer layer of the 
tumor, slightly aligned and often located close to small blood vessels and in microglia cells. In the tumors 
treated with rGO + Pro, the agglomeration of graphene particles was greatly reduced, and the particles 
were aligned in the tissue and found between cells and around cells rather than inside the cells. 
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Figure 8. Histology of U-87 glioblastoma tumors cultured on chicken embryo 
chorioallantoic membranes in the control group (A,B) and after treatment with reduced 
graphene oxide (C,D); reduced graphene oxide with arginine (E,F); and reduced graphene 
oxide with proline (G,H). Arrows point to nanoparticles. Note: Reduced graphene oxide 
flakes formed agglomerates. 
2.3.3. Gene Expression in Tumors 
Expression of the tumor protein p53 (TP53), at the mRNA level, was increased in tumors after 
treatment with rGO; however, this effect was diminished by amino acid attachment, but the level of 
TP53 after rGO + Arg treatment was higher in comparison to the control (Table 2). 
The expression of mouse double minute 2 (MDM2) was significantly higher in tumors treated with 
rGO in comparison to the control. Graphene functionalized with arginine and proline diminished this 
property; however, the expression of MDM2 was slightly but non-significantly higher than in the control 
group. The MDM2/TP53 ratio was lowest in the rGO + Arg group. The expression of cytochrome c 
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oxidase 6 (COX6) increased after treatment with all experimental treatments, with the highest expression 
found in rGO and rGO + Arg treated tumors. NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1) 
expression was increased after injection of rGO, even more after treatment with rGO + Pro and much 
more after rGO + Arg treatment. The expression of caspase-3 (CASP3) was increased in all experimental 
groups; however, this was significant only in the groups treated with rGO and rGO + Arg. Expression 
of fibroblast growth factor-2 (FGF2) was lower in all experimental groups than in the control.  
The mRNA level of vascular endothelial growth factor A (VEGF) was slightly (non-significantly) lower 
in tumors injected with rGO + Arg. 
Table 2. Gene expression at the mRNA level in glioblastoma multiforme U87 tumors, 
cultured on chicken embryo chorioallantoic membrane, after treatment with reduced 
graphene oxide, reduced graphene oxide with arginine and reduced graphene oxide with 
proline or untreated as a control. 
Genes 
Group ANOVA 
Control rGO rGO + Arg rGO + Pro SE p-Value 
TP53 0.345 a 1.310 b 0.965 c 0.604 a 0.0999 0.0001 
MDM2 0.845 a 3.053 b 1.919 a 1.564 a 0.3544 0.0065 
MDM2/TP53 2.45 a 2.33 a 1.99 b 2.59 a 0.288 0.0032 
COX6 0.323 a 0.950 c 1.082 c 0.714 b 0.0777 0.0001 
NQO1 0.380 a 3.781 b 10.845 c 5.012 b 0.2208 0.0000 
CASP3 0.428 a 0.920 b 1.052 b 0.780 a,b 0.1724 0.0115 
FGF2 1.059 a 0.671 b 0.432 b 0.741 b 0.0956 0.0045 
VEGF 0.528 0.438 0.287 0.526 0.1723 0.1156 
a,b,c Values with different letters denote a statistically significant difference between the groups. Abbreviations: 
control group (untreated); rGO: reduced graphene oxide group; rGO + Arg: reduced graphene oxide with 
arginine group; rGO + Pro: reduced graphene oxide with proline group; ANOVA: analysis of variance; and 
SE: pooled standard error. 
3. Discussion 
In the present studies we measured both mortality and viability of cells. The number of dead cells is 
a measurement of the integrity of the cell membrane, while viability is related to NAD(P)H production 
through glycolysis and correlates to the number of metabolically active cells in the culture. The results 
with experiments with GBM cells confirmed our earlier studies indicating that rGO increases cell 
mortality [10,14,35]. The toxic effects of rGO in in vitro experiments with normal and cancer cells have 
been demonstrated previously [36–39]. However, the toxic effects also depend on the type of the cells, 
as it was observed that fibroblasts (Figure 3), being less susceptible to the rGO treatment than GBM. 
This might be explained by the high amount of graphene aggregates in fibroblast medium and lower 
affinity of the rGO flakes to fibroblast cells, influencing adhesion to the cell membrane and rGO intake 
by cells. Although, the lower toxicity of rGO to fibroblasts than to GBM might be considered, the method 
of potent use of graphene as an anticancer structure presupposes direct intratumor injections. 
The toxic effect of graphene can be explained by the interaction of hydrophobic chemically active 
groups, available on the surface, with the membranes of living cells, as well as other intracellular 
structures [36–39]. However, the toxicity of graphene may be reduced after the adsorption of amino 
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acids onto graphene sheets [40]. The treatment with rGO after functionalization with amino acids led to 
significantly reduced number of dead cells compared to rGO. However, still the toxicity of rGO + Pro 
and rGO + Arg was higher than in the control group. The harmful effects of graphene might be mediated 
by hydrophobic groups exposed on the rGO surface, which became unavailable after Pro and Arg 
functionalization. In other experiments using graphene oxide (GO), the toxicity was greatly mitigated 
following extremely high protein adsorption on GO, where proteins, as a crown placed on graphene, 
decreased the number of active groups available on the surface [41]. 
Visualization of the morphology of the graphene-GBM cell interaction, as in our previous 
experiments, pointed to the affinity, adherence and entry of rGO into cells [10]. The phenomenon of 
graphene transport into cells has also been documented in other studies [13,14]. Functionalization of 
rGO by amino acids (Pro and Arg), however, dramatically changed rGO behavior. Graphene flakes, after 
administration to cultured cells, adhered to the body of cells, agglomerated, and were seen as black spots. 
Visualization of rGO + Arg and rGO + Pro did not show this kind of structure, and agglomerates of 
graphene were not seen clearly as black spots. This might suggest that the functionalization of rGO with 
Pro and Arg prevented rGO agglomeration. Shan et al. [33] demonstrated increased solubility of 
graphene after functionalization of Poly-L-lysine, what also might occur in the present experiment, 
especially that Zeta potential of rGO after functionalization with amino acids increased about two-fold. 
The results on cell viability may partially explain the above observations. rGO treatment induced 
significant cell toxicity, as well as decreased viability, but rGO + Pro and rGO + Arg only affected  
the mortality of GBM cells. We suspect that diminished agglomeration due to arginine and proline 
functionalization inhibited the entry of graphene into cells, but did not affect the intracellular mechanism, 
i.e., NAD(P)H production. The number of dead cells was reduced, but the toxicity of rGO + Arg and  
rGO + Pro was higher than in the control group, mediated by the destruction of cell membranes due to 
graphene flakes sticking to the membranes. It is likely that amino acids increased the adhesion of flakes 
to the membranes, and thereby increased their toxicity. 
In the experiment with GBM tumors cultured on the chicken embryo chorioallantoic membranes, 
rGO decreased the weight and volume of the tumors. The decreased tumor volume was accompanied by 
reduced tension of the tumor tissue, manifested by wrinkling of the surface. In our previous study, 
apoptosis of cancer cells was observed after graphene treatment [14], resulting in a reduction in tumor 
weight and volume. However, a disruption in water homeostasis might also occur, especially since 
graphene is permeable to water but not permeable to ions [42]; thus, graphene could act as a kind of 
filter, as was also suggested by Jaworski et al. [14] The volume of the tumors in rGO + Arg and  
rGO + Pro groups was smaller than in the control group but greater than in the rGO group, which was 
also confirmed by the more wrinkled surface of the tumor treated with rGO. Consequently, this may 
suggest that the proliferation of cells was decreased by all graphene treatments (rGO, rGO + Arg and 
rGO + Pro), but water circulation was changed only by rGO. 
The decreased rate of cell proliferation in the tumors after all treatments was confirmed by FGF2 
expression on the mRNA level. FGF2 is a marker of cell proliferation during tumor development; 
moreover, the dramatic effects of FGF2 in cancer result from FGF2-induced shifts in gene expression [43]. 
FGF2 is necessary for maintaining VEGFR2 receptor, hence, the inhibition of FGF2 downregulates 
VEGF-dependent biological processes, mainly angiogenesis [44]. In the present study, we observed a 
tendency for decreased VEGF expression only after rGO + Arg treatment. This result is in line with the 
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examination of the histology images from the rGO + Arg group, where graphene was found mainly  
in the outer, most metabolically active layer of the tumor, slightly aligned and often located near  
small blood vessels. This may suggest that arginine was preferentially localized in these areas. Tumor 
downregulation of the argininosuccinate synthetase results in a dependence on extracellular arginine, 
due to an inability to synthesize arginine for growth [45]. Thus, the requirement of cancer cells for 
arginine may have increased the movement of rGO + Arg molecules preferentially to the areas of most 
aggressive tumor growth. Consequently, graphene was localized in the outer layer of the tumor, in the 
area of the highly active process of angiogenesis, in contrast to rGO and rGO + Pro. 
Our previous studies did not document any anti-angiogenic effects of graphene [46], suggesting that 
the antiangiogenic effect observed in this study was induced by arginine, which was protected from 
breakdown by the association with graphene. However, the involvement of arginine in angiogenesis is 
controversial [47–49]. 
In the present experiment, the mRNA level of NQO1 increased dramatically after rGO + Arg 
treatment and to a lesser extent by rGO and rGO + Pro treatments. NQO1 promotes the two-electron 
reduction of quinones, nitroaromatics and quinoneimines and consequently depresses the quinone level, 
which minimizes the generation of reactive oxygen species [50]. Graphene-like materials, however,  
can protect molecular targets from oxidation by free radicals, and are highly effective scavengers of 
hydroxyl radical [51]. Furthermore, NQO1 plays a broad role in cytoprotection because it binds to and 
consequently stabilizes the tumor suppressor p53 protein from proteasomal degradation [52]. In the 
present experiments, however, the expression of TP53 at the mRNA level also increased after rGO + 
Arg and to a higher degree after rGO application. Furthermore, rGO upregulated the expression of TP53, 
indicating a dual role of rGO by stimulation of the TP53 gene and by stimulation of the protector of p53, 
NQO1. As a key tumor suppressor, p53 inhibits tumorigenesis by inducing cell cycle arrest, senescence, 
and apoptosis [53]. Apoptosis of GMB cells as a result of rGO treatment was observed in our earlier 
experiments [10,14]. The present experiments confirm these results, demonstrating the upregulation of 
CASP3, which plays a key role in the execution phase of apoptosis. 
During stress, the expression of p53 increases in glioma [54], but its actual activity is determined  
by the level of MDM2, which binds to the N-terminal domain of p53 and blocks its proapoptotic  
activity [55]. Some authors believe that blocking the binding of p53 with MDM2 by selective blocking 
of the MDM2 binding domain without deregulation and deactivation of p53 protein could benefit 
anticancer therapy [56,57]. In all experimental groups, increased expression of MDM2 at the mRNA 
level was observed. However, the MDM2/TP53 index was significantly lower only in rGO + Arg treated 
tumors. This raises the issue that only the interaction of graphene and arginine may modify molecular 
responses in the most promising direction. 
TP53 has several polymorphisms, including a proline to arginine variant at amino acid 72 (P72 to R72). 
The P72 variant induces cell cycle arrest, while the R72 variant has the ability to preferentially induce 
apoptosis [53]. Thus, we can hypothesize that an additional reservoir of arginine, provided and protected 
against enzymatic digestion by the rGO platform [58], may support the synthesis of DNA for properly 
encoded TP53 with the R72 polymorphism (arginine variant). This is in line with the results concerning 
CASP3-mediated activation of apoptosis. 
Considering the results of rGO + Pro administration in comparison to rGO + Arg, the MDM2/TP53 
index and reduced expression of NQO1 indicate the insufficient effect of this complex. The data may 
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also confirm that, in the case of TP53 with the R72 polymorphism, supplementation with proline has no 
impact on the mRNA expression of TP53. 
Interestingly, COX6 mRNA expression was significantly induced by rGO and rGO + Arg and to  
a lesser degree by rGO + Pro. The intrinsic pathway of apoptosis occurs by releasing COX6 into the 
cytosol, which then causes the assembly of a multiprotein caspase-activating complex [59]. p53 activates 
this mechanism in a transcriptionally-dependent or -independent manner [60]. In our experiments, the 
activation of TP53 and COX6 transcription was similar, i.e., higher in the rGO and rGO + Arg treatments 
and lower in the control and rGO + Pro groups. Considering these results, as well as decreased CASP3 
expression mediated by rGO + Pro, may indicate that proline attached to graphene reduces the 
proapoptotic activity of rGO. 
4. Experimental Section 
4.1. Preparation of Graphene Complexes 
Graphene oxide (GO) was prepared from natural graphite flakes (purchased from Asbury Carbons, 
Asbury, NJ, USA) by a modified Hummers method [14]. To prepare the reduced graphene oxide (rGO), 
a water suspension of 50 mg of GO was acidified to pH 1 and heated to 90 °C. In the next step, 12 mL 
of reducing mixture (0.01 g of ammonium iodide, 9 g of hydrated sodium hypophosphite, and 1.21 g of 
sodium sulfite dissolved in 100 mL of deionized water) was added. A black material (rGO) precipitated 
immediately. The product was filtered, washed with deionized water, and dried. The rGO powders  
were used to make aqueous suspensions for further analysis and applied in experiments. The aqueous 
suspensions were done by adding the powder to ultrapure water and sonicating the solution at 550 W/m2 
for 1 h. To prepare graphene + L-arginine (rGO + Arg) or graphene + L-proline (rGO + Pro) complexes, 
the amino acid (mass ratio of 1:1) was added to the GO aqueous suspension and mixed on a magnetic 
stirrer to dissolve the amino acid. Then, a mixture of reducers, i.e., sodium hypophosphite (0.5 g) and 
hydroiodic acid (5 mL at a concentration of 57%) was added. The process of reduction was conducted 
for approximately 3 h at a temperature of 80 °C. At the end of the procedure, gentle sonication of the 
sample was performed. The procedure was the same with each of the amino acids (arginine and proline). 
L-arginine and L-proline were obtained from Sigma-Aldrich (St. Louis, MO, USA). In the preliminary 
tests we have established the quantity of amino acids, linked with graphene without leaving residues of 
graphene, as 1:1 proportion of amino acid to graphene. Ninhydrine (2,2-Dihydroxyindane-1,3-dione) 
was used to detect amino acids in the washed out fluid. 
The size and shape of the graphene sheets were examined by a JEM-1220 (JEOL, Tokyo, Japan) 
transmission electron microscope (TEM) at 80 KeV, with a Morada 11-megapixel camera  
(Olympus Soft Imaging Solutions, Münster, Germany). The samples for TEM were prepared by placing 
droplets of hydrocolloids on to Formvar-coated copper grids (Agar Scientific, Stansted, UK). The 
droplets were dried in dry air, and immediately the grids were inserted into the TEM. The tests were 
performed in triplicate. 
The ζ potential in water was measured by a Zetasizer Nano ZS model ZEN3500 (Malvern Instruments, 
Malvern, UK). The FTIR spectra were measured by Vertex 80v (Bruker BioSpin Corporation,  
Billerica, MA, USA) in the range 500 to 4000 cm−1. 
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4.2. Cell Culture 
The human glioblastoma U87 and fibroblast L929 cell lines were purchased from the American Type 
Culture Collection (Manassas, VA, USA) and maintained in Dulbecco’s Modified Eagle’s culture 
medium containing 10% fetal bovine serum (Life Technologies, Houston, TX, USA) and 1% penicillin 
and streptomycin (Life Technologies) at 37 °C in a humidified atmosphere of 5% CO2/95% air in a DH 
AutoFlow CO2 air-jacketed incubator (NuAire, Plymouth, MN, USA). 
4.3. Cell Morphology 
U87 glioma cells were seeded in six-well plates (1 × 105 cells per well) and incubated for 24 h. Cells 
cultured in the medium without any treatment were used as the control group. Graphene and amino acid 
complexes, at a concentration of 50 μg/mL of rGO and 50 μg/mL of arginine or proline, were introduced 
to the cells. 24 h after exposure, an optical microscope was used to evaluate cell morphology. 
4.4. Cell Mortality 
The trypan blue assay (Sigma-Aldrich, St. Louis, MO, USA) was used to evaluate cell mortality.  
U87 cells were plated in 96-well plates (5 × 105 cells per well) and incubated for 24 h. The medium was 
removed, and rGO, rGO + Arg, or rGO + Pro samples were introduced to the cells. Then, the cells were 
detached with 300 μL of a trypsin-ethylenediaminetetraacetic acid (EDTA) solution. The mixture was 
centrifuged at 1200 rpm for 3 min. In the next step, 700 μL of trypan blue solution was added to each 
well and dispersed. After 5 min, the cells were counted using a CellCounter (Roche, Penzberg, Germany). 
Dead cells were stained blue. Cell mortality was expressed as the percentage of the dead cells in 
proportion to the total cell number. 
4.5. Cell Viability 
Cell viability was determined using a 2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-
carboxyanilide salt (XTT)-based cell proliferation assay kit (Life Technologies, Taastrup, Denmark). 
U87 were plated in 96-well plates (5 × 103 cells per well) and incubated for 24 h. The medium was  
then removed, and rGO and rGO + Arg, or rGO + Pro samples were introduced to the cells (at the 
concentration described above). In the next step, 50 μL of XTT solution was added to each well and 
incubated for an additional 3 h at 37 °C. The optical density of each well was recorded at 450 nm on an 
enzyme-linked immunosorbent assay reader (Infinite M200, Tecan, Durham, NC, USA). Cell viability 
was expressed as the percentage (ODtest − ODblank)/(ODcontrol − ODblank), where ODtest is the optical 
density of cells exposed to GO and rGO, ODcontrol is the optical density of the control sample, and ODblank 
is the optical density of wells without glioma cells. The same procedure was used with fibroblasts L929 
and glioblastoma U87 cells treated with rGO. 
4.6. Culture of GMB on a Chorioallantoic Membrane 
The fertilized eggs (Gallus gallus; n = 80) were obtained from a commercial hatchery (Dębówka, 
Poland). After 6 days of incubation (under standard conditions), a silicone ring ×10 containing  
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3–4 × 106 U87 cells, suspended in 30 μL of culture medium, was placed on the chorioallantoic 
membrane. The eggs were incubated for the following 7 days, and then randomly divided into four 
groups (n = 20 each): control not injected and rGO, rGO + Arg and rGO + Pro, injected with 200 μL of 
each solution. The concentration of rGO, rGO + Arg or rGO + Pro was 500 μL of rGO and 500 μL of 
arginine or proline. The solutions were directly injected into the tumor tissue. After 3 days, the tumors 
were resected for pending analysis. 
4.7. Tumor Volume and Histology 
A stereomicroscope (SZX10, CellD software version 3.1; Olympus Corporation, Tokyo, Japan) was 
used to take digital photographs of the tumors. The measurements were performed with cellSens 
Dimension Desktop version 1.3 (Olympus). The tumor volumes were calculated using the method 
described by Jaworski et al. [14]. 
After resection, tumors were fixed in 4% buffered formalin (Sigma-Aldrich, St. Louis, MO, USA). 
Samples were dehydrated and embedded in paraffin. Sections 5 μm in thickness were placed on  
poly-L-lysine-coated slides (Equimed, Krakow, Poland) and stained with hematoxylin and eosin.  
The measurements were carried out using an optical microscope DM750; Leica Microsystems GmbH, 
(Wetzlar, Germany) and LAS EZ version 2.0 software (Wetzlar, Germany). Morphometric estimation 
and image analysis were made using 20 measurements of each sample at 400× magnification. The 
mitotic index was evaluated as the number of mitotic figures in ten visual fields. 
4.8. Gene Expression at the mRNA Level 
The tumor tissue samples were homogenized in TRIzol® Reagent (Thermo Fisher Scientific, 
Waltham, MA, USA), and total RNA was extracted according to the manufacturer’s instructions. The 
RNA was purified using the SV Total RNA Isolation System (Promega Corporation, Madison, WI, USA) 
and quantitated using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). Quality was further measured using an Agilent 2100 bioanalyzer (Agilent RNA 6000 Nano kit, 
Waldbronn, Germany). The RNA integrity number (RIN) higher than 6.5 was considered acceptable to 
proceed with complementary DNA (cDNA) synthesis. Using 2 µg of total RNA was reverse transcribed 
for cDNA synthesis, after which real-time PCR was performed with cDNA and the gene specific primers 
shown in Table 3 (TAG, Copenhagen A/S, Copenhagen, Denmark) mixed with SYBR Green Master 
mix (Roche Applied Science, Penzberg, Germany) in a Light Cycler® 480 real-time PCR system (Roche 
Applied Science, Penzberg, Germany). The cycling conditions included with an initial denaturing step 
at 95 °C for 15 min, followed by 40 cycles with a denaturing step at 94 °C (15 s), an annealing step at 
56 °C (30 s), and an elongation step at 72 °C (60 s). The cycling reports and melting curves were 
evaluated as part of the analysis. Each individual sample reaction was performed in triplicate.  
For analyses, relative quantification was calculated versus expression of the β actin (ACTB)  
reference gene. 
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Table 3. Primers used in the study. 
Gene Forward Primer (5′–3′) Reverse Primer (5′–3′) 
TP53 CCCAGCCAAAGAAGAAACCA TTCCAAGGCCTCATTCAGCT 
MDM2 CAGGACATCTTATGGCCTGCTT GGGCAGGGCTTATTCCTTTT 
COX6 TGAATCCGGGGTGCCTTTAG CAGAGGGACTGGTACACACG
NQO1 AGGCTGGTTTGAGCGTGTTC TTGAATTCGGGCGTCTGCTG 
CASP3 ACATGGCGTGTCATAAAATACC CACAAAGCGACTGGATGAAC
FGF2 GGCACTGAAATGTGCAACAG TCCAGGTCCAGTTTTTGGTC 
VEGFA TGAGGGCCTAGAATGTGTCC TCTTTTGACCCTTCCCCTTT 
ACTB ACCCAGATCATGTTCGAGACCTT TCACCGGAGTCCATCACGAT 
Abbreviations: TP53, tumor protein p53; MDM2, mouse double minute 2; COX6, cytochrome c oxidase subunit 
VIb polypeptide 1; NQO1, NAD(P)H: quinone acceptor oxidoreductase 1; CASP3, caspase-3; FGF2, fibroblast 
growth factor-2; VEGFA, vascular endothelial growth factor A; ACTB, β-actin. 
5. Conclusions 
This study confirmed the anticancer effect of reduced graphene oxide on glioblastoma multiforme 
cells, cultured in vitro as well as in tumor tissue in vivo. Moreover, rGO activated TP53 gene expression, 
which is responsible for cellular protection and the stress response, and consequently increased the 
expression of COX6 and CASP3 involved in apoptosis. Interestingly, the NQO1 gene, responsible for 
quinone and nitroaromatic reduction and protection of p53 from proteasomal degradation, was activated. 
This may indicate a new mechanism of the anticancer activity of graphene. However, flakes of rGO after 
introduction to cells were agglomerated and randomly spread, which decreased its surface area and 
interfered with the distribution of rGO within the tumor. 
After functionalization with amino acids, rGO was distributed more specifically, and flakes of 
graphene were less agglomerated. Undoubtedly, amino acids directed the distribution of graphene within 
the tumor, playing the role of tailoring molecules. Moreover, arginine but not proline enhanced the 
anticancer activity of rGO at the molecular level. The rGO + Arg molecule, however, did not increase 
the expression of TP53 in comparison to rGO, but also did not increase the expression of MDM2 (a key 
protein in binding and deactivating p53) or the MDM2/TP53 ratio in the tumor, suggesting that arginine 
may block MDM2 expression. Furthermore, rGO + Arg did not diminish COX6 and CASP3 mRNA 
expression, which were increased by rGO treatment, indicating that the pro-apoptotic character of  
rGO was not reduced by arginine functionalization. The most important result was that rGO + Arg 
strongly increased the expression of NQO1 in tumor tissue, which may have decreased the generation of 
reactive oxygen. 
Acknowledgments 
This work was supported by the Polish National Research Council (grant 2011/03/B/NZ9/03387). 
Author Contributions 
Ewa Sawosz conceived, designed and performed the experiments, analysed data and wrote the paper; 
Sławomir Jaworski helped in experiments and sample collection from in vivo and in vivo experiments; 
Int. J. Mol. Sci. 2015, 16 25230 
 
 
Marta Kutwin and Krishna Prasad Vadalasetty performed mRNA gene expression; Marta Grodzik 
helped in analysing data and preparation of the paper; Mateusz Wierzbicki performed experiments with 
cells; Natalia Kurantowicz and Barbara Strojny performed experiments witch chrioallantoic membrane; 
Anna Hotowy performed total RNA isolation and cDNA preparation; Ludwika Lipińska and  
Joanna Jagiełło characterized graphene particles and manufactured rGO and amino acid complexes; and 
André Chwalibog conceived, designed experiments and wrote the paper. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Walker, C.; Baborie, A.; Crooks, D.; Wilkins, S.; Jenkinson, M.D. Biology, genetics and imaging 
of glial cell tumours. Br. J. Radiol. 2011, 84, 90–106. 
2. DeAngelis, L.M. Medical progress: Brain tumors. N. Engl. J. Med. 2001, 344, 114–123. 
3. Parson, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; 
Siu, I.M.; Gallia, G.L.; et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. 
Science 2008, 321, 1807–1812. 
4. Shakur, S.F.; Bit-Ivan, E.; Watkin, W.G.; Merrell, R.T.; Farhat, H.I. Multifocal and multicentric 
glioblastoma with leptomeningeal gliomatosis: A case report and review of the literature.  
Case Rep. Med. 2013, 2013, 132679. 
5. Kesari, S. Understanding glioblastoma tumor biology: The potential to improve current diagnosis 
and treatments. Semin. Oncol. 2011, 38, S2–S10. 
6. Geim, A.K.; Novoselov, K.S. The rise of graphene. Nat. Mater. 2007, 6, 183–191. 
7. Liu, Z.; Robinson, J.T.; Sun, X.; Dai, H. PEGylated nanographene oxide for delivery of  
water-insoluble cancer drugs. J. Am. Chem. Soc. 2008, 130, 10876–10877. 
8. Liu, J.; Cui, L.; Losic, D. Graphene and graphene oxide as new nanocarriers for drug delivery 
applications. Acta Biomater. 2013, 9, 9243–9257. 
9. Sun, X.M.; Liu, Z.; Welsher, K.; Robinson, J.T.; Godwin, A. Nano-graphene oxide for cellular 
imaging and drug delivery. Nano Res. 2008, 1, 203–212. 
10. Jaworski, S.; Sawosz, E.; Grodzik, M.; Winnicke, A.; Prasek, M.; Wierzbicki, M.; Chwalibog, A. 
In vitro evaluation of the effects of graphene platelets on glioblastoma multiforme cells.  
Int. J. Nanomed. 2013, 8, 413–420. 
11. Fiorillo, M.; Verre, A.F.; Iliut, M.; Peiris-Pagés, M.; Ozsvari, B.; Gandara, R.; Cappello, A.R.; 
Sotgia, F.; Vijayaraghavan, A.; Lisanti, M.P. Graphene oxide selectively targets cancer stem cells, 
across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based 
nano-therapy”. Oncotarget 2015, 6, 3553–3562. 
12. Konios, D.; Stylianakis, M.M.; Stratakis, E.; Kymakis, E. Dispersion behaviour of graphene oxide 
and reduced graphene oxide. J. Colloid Interface Sci. 2014, 430, 108–112. 
13. Sawosz, E.; Jaworski, S.; Kutwin, M.; Hotowy, M.; Wierzbicki, M.; Grodzik, M.; Strojny, B.; 
Lipinska, L.; Chwalibog, A. Toxicity of pristine graphene in experiments in a chicken embryo 
model. Int. J. Nanomed. 2014, 9, 3913–3922. 
Int. J. Mol. Sci. 2015, 16 25231 
 
 
14. Jaworski, S.; Sawosz, E.; Kutwin, M.; Wierzbicki, M.; Hinzmann, M.; Grodzik, M.; Winnicka, A.; 
Lipinska, L.; Wlodyga, K.; Chwalibog, A. In vitro and in vivo effects of graphene oxide and reduced 
graphene oxide on glioblastoma multiforme. Int. J. Nanomed. 2015, 10, 1–12. 
15. Marchesan, S.; Prato, M. Under the lens: Carbon nanotube and protein interaction at the nanoscale. 
Chem. Commun. 2015, 51, 4347–4359. 
16. Huges, Z.E.; Walsh, T.R. What makes a good graphene-binding peptide? Adsorption of amino acids 
and peptides at aqueous graphene interfaces. J. Mater. Chem. B 2015, 3, 3211–3221. 
17. Kay, B.K.; Williamson, M.P.; Sudol, M. The importance of being proline: The interaction of  
proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 2000, 14, 231–241. 
18. Krane, S.M. The importance of proline residues in the structures stability and susceptibility to 
proteolityc degradation of collagen. Amino Acids 2008, 35, 703–7010. 
19. Betts, M.J.; Russell, R.B. Amino acids properties and consequences of substitution. In 
Bioinformatics for Geneticists, 2nd ed.; Barnes, M.R., Gray, I.C., Eds.; Wiley: Hoboken, NJ, USA, 
2003; pp. 311–343. 
20. Hamasu, K.; Haraguchi, T.; Kabuki, Y.; Adachi, N.; Tomonaga, S.; Sato, H.; Denbow, D.M.; 
Furuse, M. L-Proline is a sedative regulator of acute stress in the brain of neonatal chicks.  
AMINO ACIDS 2009, 37, 377–382. 
21. Phang, J.M.; Liu, W.; Hancock, C.; Christian, K.J. The proline regulatory axis and cancer.  
Front. Oncol. 2012, 2, 60. 
22. Phang, J.M.; Donald, S.P.; Pandhare, J.; Liu, Y. The metabolism of proline, a stress substrate 
modulates carcinogenic pathway. Amino Acids 2008, 4, 726–745. 
23. Bond, G.L.; Hu, W.; Levine, A.J. 2MDM2 is a central node in the p53 pathway: 12 years and 
counting. Curr. Cancer Drug Targets 2005, 6, 3–8. 
24. Murphy, M.E. Regulation of IAP (Inhibitor of Apoptosis) Gene Expression by the p53 Tumor 
Expression Protein; Army Medical Research and Materiel Command Fort Detrick, Fox Chase 
Cancer Center: Philadelphia, PA, USA, 2005. 
25. Jansson, M.; Durant, S.T.; Cho, E.-C.; Sheahan, S.; Edelmann, M.; Kessler, B.; la Thangue, N.B. 
Arginine methylation regulates the p53 response. Nat. Cell Biol. 2008, 10, 1431–1439. 
26. Jeong, B.-S.; Hu, W.; Belyi, V.; Rabadan, R.; Levine, A.J. Differential levels of transcription of 
p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors 
apoptosis. FASEB J. 2010, 24, 1347–1353. 
27. Lin, W.-T.; Yang, S.-C.; Chen, K.-T.; Huang, C.-C.; Lee, N.-Y. Protective effects of L-arginine  
on pulmonary oxidative stress and antioxidant defenses during exhaustive exercise in rats.  
Acta Pharmacol. Sin. 2005, 26, 992–999. 
28. Yeatman, T.J.; Risley, G.L.; Brunson, M.E. Depletion of dietary arginine inhibits growth of 
metastatic tumor. Arch. Surg. 1991, 126, 1376–1381. 
29. Roomi, M.W.; Ivanov, V.; Kalinovsky, T.; Niedzwiecki, A.; Rath, M. Antitumor effect of ascorbic 
acid, lysine, proline, arginine, and green tea extract on bladder cancer cell line T-24. Int. J. Urol. 
2006, 13, 415–419. 
30. Shu, X.; Liu, X.L.; Zhong, J.X.; Liu, J. L-Arginine enhance arginine deaminase induced human 
lymphoma cell growth inhibition through NF-κBp65 and p53 expression in vitro. Eur. Rev. Med. 
Pharmacol. Sci. 2014, 18, 2124–2131. 
Int. J. Mol. Sci. 2015, 16 25232 
 
 
31. Kurantowicz, N.; Sawosz, E.; Jaworski, S.; Kutwin, M.; Strojny, B.; Wierzbicki, M.; Szeliga, J.; 
Hotowy, A.; Lipińska, L.; Kozinski, R.; et al. Interaction of graphene family materials with  
Listeria monocytogenes and Salmonella enterica. Nanoscale Res. Lett. 2015, 10, 23. 
32. Kumar, S.; Rai, S.B. Spectroscopic studies of L-arinine molecule. Indian J. Pure Appl. Phys. 2010, 
48, 251–255. 
33. Shan, C.; Yang, H.; Han, D.; Zhang, Q.; Ivasak, A.; Niu, L. Water-soluble graphene covalently 
funcionalized by biocompatible poly-L-lysine. Langimuir 2009, 25, 12030–12033. 
34. Singh, S.K.; Singh, M.K.; Kulkarni, P.P.; Sonkart, C.K.; Grácio, J.J.A. Amine-modified graphene: 
Thrombo-protective safer alternative to graphene oxide for biomedical applications. ACS Nano 
2012, 6, 2731–2740. 
35. Hinzmann, M.; Jaworski, S.; Kutwin, M.; Jagiełło, J.; Koziński, R.; Wierzbicki, M.; Grodzik, M.; 
Lipińska, L.; Sawosz, E.; Chwalibog, A. Nanoparticles containing allotropes of carbon have 
genotoxic effects on glioblastoma multiforme cells. Int. J. Nanomed. 2014, 9, 2409–2417. 
36. Liao, K.-H.; Lin, Y.-S.; Macosko, C.W.; Haynes, C.L. Cytotoxicity of graphene oxide and graphene 
in human erythrocytes and skin fibroblasts. ACS Appl. Mater. Interfaces 2011, 3, 2607–2615. 
37. Saebra, A.B.; Paula, A.J.; de Lima, R.; Alves, O.L.; Duran, N. Nanotoxicity of graphene and 
graphene oxide. Chem. Res. Toxicol. 2014, 27, 159–168. 
38. Bianco, A. Graphene: Safe or toxic? The two faces of the medal. Angew. Chem. Int. Ed. Engl. 2013, 
52, 4986–4997. 
39. Chang, Y.; Yang, S.-T.; Liu, J.-H.; Dong, E.; Wang, Y.; Cao, A.; Liu, Y.; Wang, H. In vitro toxicity 
evaluation of graphene oxide on A549 cells. Toxicol. Lett. 2011, 200, 201–210. 
40. Sanchez, V.C.; Jachak, A.; Hurt, R.H.; Kane, A.B. Biological Interactions of graphene-family 
nanomaterials: An interdisciplinary review. Chem. Res. Toxicol. 2012, 25, 15–34. 
41. Hu, W.; Peng, C.; Lv, M.; Li, X.; Zhang, Y.; Chen, N.; Fan, C.; Huang, Q. Protein corona-mediated 
mitigation of cytotoxicity of graphene oxide. ACS Nano 2011, 5, 3693–3700. 
42. Cohen-Tanugi, D.; Grossman, J.C. Water desalination across nanoporous graphene. Nano Lett. 
2012, 12, 602–608. 
43. Kottakis, F.; Polytarchou, C.; Foltopoulou, P.; Sanidas, I.; Kampranis, S.C.; Tsichlis, P.N. FGF-2 
regulates cell proliferation, migration and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 
pathway. Mol. Cell 2011, 43, 285–298. 
44. Murakami, M.; Nguyen, L.T.; Hatanaka, K.; Schachterle, W.; Chen, P.-Y.; Zhuang, Z.W.; Black, B.L.; 
Simons, M. FGF-dependent regulation of VEGF receptor 2 expression in mice. J. Clin. Investig. 
2011, 121, 2668–2678. 
45. Delage, B.; Fennell, D.A.; Nicholson, L.; McNeish, I.; Lemoine, N.R.; Crook, T.; Schlosarek, P.W. 
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.  
Int. J. Cancer 2010, 126, 2762–2772. 
46. Wierzbicki, M.; Sawosz, E.; Grodzik, M.; Prasek, M.; Jaworski, S.; Chwalibog, A. Comparison of 
anti-angiogenic properties of pristine carbon nanoparticles. Nanoscale Res. Lett. 2013, 8, 195. 
47. Bae, D.-G.; Gho, Y.-S.; Yoon, W.-H.; Chae, C.-B. Arginine-rich anti-vascular endothelial growth 
factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J. Biol. Chem. 2000, 
275, 13588–13596. 
Int. J. Mol. Sci. 2015, 16 25233 
 
 
48. Yeh, C.-L.; Pai, M.-H.; Li, C.-C.; Tsai, Y.-L.; Yeh, S.-L. Effect of arginine on angiogenesis induced 
by human colon cancer: In vitro and in vivo studies. J. Nutr. Biochem. 2010, 21, 538–543. 
49. Kettenmann, H.; Hanisch, U.K.; Verkhratsky, A. Physiology of microglia. Physiol. Rev. 2011, 91, 
461–553. 
50. Ross, D.; Kepa, J.K.; Winski, S.; Beall, H.D.; Anwar, A.; Siegel, D. NAD(P)H:Quinone 
oxidoreductase 1 (NQO1): Chemoprotection, bioactivation, gene regulation and genetic 
polymorphisms. Chem. Biol. Interact. 2000, 129, 77–97. 
51. Qiu, Y.; Wang, Z.; Owens, A.C.; Kulaots, I.; Chen, Y.; Kane, A.B.; Hurt, R.H. Antioxidant 
chemistry of graphene-based materials and its role in oxidation protection technology. Nanoscale 
2014, 6, 11744–11755. 
52. Dinkova-Kostova, A.T.; Talay, P. NAD(P)H:Quinone acceptor oxidoreductase 1 (NQO1), a 
multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys. 
2010, 501, 116–123. 
53. Kung, C.P.; Khaku, S.; Jennis, M.; Murphy, M.E. Identification of TRIML2, a novel p53 target, 
that enhances p53 SUMOylation and regulates the transactivation of pro-apoptotic genes.  
Mol. Cancer Res. 2015, 13, 250–262. 
54. Bonini, P.; Cicconi, S.; Cardinale, A.; Vitale, C.; Serafino, A.L.; Ciotti, M.T.; Marlier, N.J.-L. 
Oxidative stress induces p53-mediated apoptosis in glia: p53 transcription- independent way to die. 
J. Neurosci. Res. 2004, 75, 83–95. 
55. Meulmeester, E.; Jochemsen, A.G. p53: A guide to apoptosis. Curr. Cancer Drug Targets 2008, 8, 
87–97. 
56. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; 
Lukacs, C.; Klein, C.; et al. In vivo activation of the p53 pathway by small-molecule antagonists of 
MDM2. Science 2004, 303, 844–848. 
57. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; 
Reczek, E.E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumour regression  
in vivo. Nature 2007, 8, 661–665. 
58. Lei, H.Z.; Mi, L.J.; Zhou, X.J.; Lei, H.; Mi, L.; Zhou, X.; Chen, J.; Hu, J.; Guo, S.; Zhang, Y. 
Adsorption of double-stranded DNA to graphene oxide preventing enzymatic digestion. Nanoscale 
2011, 3, 3888–3892. 
59. Green, D.R.; Reed, J.C. Mitochondria and apoptosis. Science 1998, 281, 1309–1312. 
60. Haupt, S.; Berger, M.; Goldberg, Z.; Haupt, Y. Apoptosis—The p53 network. J. Cell Sci. 2003, 
116, 4077–4085. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
